BIOMARIN PHARMACEUTICAL INC (BMRN)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$3,072.4M
Cash & Equivalents
$220.7M
Quarterly Burn Rate
$11,427M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (2 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
GALSULFASE
NAGLAZYME |
APPROVED | Achondroplasia, Acid Sphingomyelinase Deficiency, Advanced Breast Cancer, Albuminuria, Alpha 1-Antitrypsin Deficiency, ATP-Binding Cassette Subfamily C Member 6 Deficiency, Autism Spectrum Disorder, Autistic Disorder, Autosomal Recessive Hypophosphatemic Rickets, Batten Disease, Behavior and Behavior Mechanisms, Behavioral Manifestations of Lesch-Nyhan Disease, Blood Disorder, Carcinoma, Non-Small-Cell Lung, Cardiovascular Disease, Cerebrotendinous Xanthomatosis, Ceroid Lipofuscinosis, Neuronal, 2, Childhood Solid Tumors, Classical Phenylketonuria(PKU), Claudication, Intermittent, CLN2, CLN2 Disease, CLN2 Disorder, Clotting Disorders, Cognitive Decline, Coronary Artery Disease, Duchenne Muscular Dystrophy, Duchenne Muscular Dystrophy (DMD), Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Endothelial Dysfunction, Fabry Disease, Gaucher Disease, Gene Therapy, Generalized Arterial Calcification of Infancy, Generalized Arterial Calcification of Infancy 1, GM1 Gangliosidosis, GTP Cyclohydrolase Defic |
|
LARONIDASE
ALDURAZYME |
APPROVED | — |
Upcoming Catalysts
No upcoming catalysts detected for this company.